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Abstract: Feline immunodeficiency virus (FIV) is widespread in feline populations and 
causes an AIDS-like illness in domestic cats. It is highly prevalent in several endangered 
feline species. In domestic cats FIV infection is a valuable small animal model for HIV 
infection. In recent years there has been a significant increase in interest in FIV, in part to 
exploit this, but also because of the potential it has as a human gene therapy vector. 
Though much less studied than HIV there are many parallels in the replication of the two 
viruses, but also important differences and, despite their likely common origin, the viruses 
have in some cases used alternative strategies to overcome similar problems. Recent 
advances in understanding the structure and function of FIV RNA and proteins and their 
interactions has enhanced our knowledge of FIV replication significantly, however, there 
are still many gaps. This review summarizes our current knowledge of FIV molecular 
biology and its similarities with, and differences from, other lentiviruses. 
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1. Introduction 
Feline immunodeficiency virus (FIV) is a lentivirus infecting different species of cat and causing, in 
some, a pathology similar to that of HIV-1 infection in humans [1,2]. Species-specific strains of FIV 
circulate in many feline populations [3,4]. Domestic cats infected with FIV develop a progressive 
immune dysfunction characterised by depletion of CD4+ T cells; eventually signs of cachexia, 
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appearance of many new N-glycosylation sites within this loop [21] and an insertion of just two 
residues at position 556-7 re-sensitises escape mutants to neutralisation [22]. Mutation of the other 
variable loops is common with the V1,V2 and V4 regions also showing variations in glycosylation 
pattern [21]. Pressure on the virus to mutate these variable loops can also lead to an alteration in the 
Env-receptor interactions. Advancing HIV-1 infection is often associated with a broadening cell 
tropism of the viral quasispecies. Co-receptor specificity of some of these species shifts from CCR5 to 
CXCR4, allowing the virus to infect different cell types. FIV seems only to use CXCR4 as a 
co-receptor, but, like HIV it shifts its cell tropism during the course of infection. This has been 
proposed to occur not by binding of a new co-receptor, but by a decreased dependence on CD134 
(reviewed in [23]). Thus, as infection progresses, new Env variants are able to infect cells that express 
CXCR4 with limited amounts of CD134, such as naïve B cells and CD8 T cells [24,25]. Introduction 
of a lysine at residue 407 or 409 allows CXCR4 to be used as the sole receptor [26–28]; interestingly, 
these lysine residues have also been shown to be important for interaction with heparan sulfate 
proteoglycans [29], which play a role in the cellular attachment of some strains of both FIV and HIV 
[27,30]. Disruption of the glycosylation site at position 269 of the V1,V2 loop homolog is also thought 
to contribute towards CD134 independence [21,31]. Viruses that require CD134 as a primary receptor 
appear to bind to it via a complex interaction involving cysteine-rich domains 1 and 2, but as infection 
progresses the interaction becomes less complex and the interaction with CRD2 decreases [32]. Some 
researchers claim that the mutation rate of Env is low and have not observed these changes [33,34] 
however it is likely to be influenced by the replication rate of the FIV strain used.  
Interestingly, some strains of lion FIV show a substantial divergence in structure and sequence of 
the envelope receptor binding domains and do not enter via CXCR4 and/or CD134 [35,36]. The 
cellular receptors for these subtype B lion FIVs have not yet been identified.  
Table 1. Major functions of the FIV proteins. 
Protein 
Precursor 
Functional Cleavage 
Products 
Major Attributed Functions 
Gag Matrix  Virion  structural protein 
  Capsid  Virion structural protein 
  Nucleocapsid  Binding to viral genome 
Pol Protease 
Cleavage of Gag and Gag-Pol precursor proteins, leading to 
virion maturation 
  Reverse Transcriptase   Reverse transcription of the genomic RNA into proviral DNA 
 
Deoxyuridine 
triphosphatase 
Limitation of uracil misincorporation during reverse 
transcription 
 Integrase  Integration  of  proviral DNA into host chromosome 
Vif    Counteraction of host cell cytidine deaminases 
OrfA  
Possible roles in transcriptional activation, control of splicing, 
virion dissemination 
Rev    Nuclear export of partially spliced /unspliced RNA transcripts 
Env 
Surface and 
transmembrane 
subunits 
Virion attachment and entry into target cells Viruses 2011, 3        
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3. Reverse Transcription 
After entry and uncoating, the single-stranded RNA genome is converted into double-stranded DNA 
by the process of reverse transcription. This commences from the tRNA primer, which is annealed to 
the primer binding site (PBS) of the viral genomic RNA. Extension from this primer towards the 5'end 
of the genome generates minus-strand strong-stop DNA. RNase H activity of the reverse transcriptase 
(RT) catalyses the removal of the RNA to leave single-stranded DNA. This new strand anneals via a 
complementary sequence to the 3'end of the genomic RNA where it acts as a primer for polymerisation 
of a DNA copy of the remainder of the RNA template. RNA fragments which resist RNase 
degradation are left at the polypurine tracts (PPTs) present in the centre of the genome (cPPT) and 
towards the 3'end (PPT) and act as primers for second strand synthesis. Polymerisation from the PPT 
halts at the first modified base of the primer tRNA and the product is known as plus-strand strong stop 
DNA. The RNase H domain of RT then degrades the tRNA and the 3'end of plus-strand strong stop 
DNA anneals to a complementary sequence at the 5'end of the minus-strand template to continue the 
plus strand and also allow completion of the minus-strand. This generates a double-stranded DNA 
provirus with long-terminal repeats and a central DNA flap at the cPPT. FIV RT utilises the same 
cellular tRNA primer as HIV-1 [37] yet it is unable to initiate reverse transcription on an HIV-1 
template [38]. Reverse transcription initiation in lentiviruses seems to be regulated by an interaction 
between exposed nucleotides of the tRNA primer and part of the upstream genomic RNA (reviewed 
in  [39]) however the sequences involved vary between viruses. In FIV initiation of reverse 
transcription is thought to be controlled by an interaction of the extreme 5' nucleotides of the tRNA 
primer with a conserved stem-loop in the U5 region [38]. It is not known how progress of the RT 
through this stem-loop structure is governed but the block to reverse transcription in FIV appears to be 
less tightly controlled than in other retroviruses as a diverse range of retroviral RTs can extend 
efficiently on the FIV genome, whereas FIV RT could not extend on an HIV-1 genome unless the 
interaction between the tRNA primer and an A-rich upstream sequence was disrupted [37].  
In FIV, unusually the two PPTs are different in sequence from one another. Unlike in HIV-1 and 
certain other retroviruses, the cPPT contains one or two pyrimidine residues, although it remains 
functionally similar to other cPPTs in initiating plus-strand synthesis and producing a DNA flap [40] 
which is suggested in HIV to be involved in nuclear import [41]. There is also the possibility that 
initiation from the central flap protects against G to A transition mutations caused by cytidine 
deaminase action during reverse transcription (discussed below, [42]).  
FIV RT shares 63% nt identity and 67% amino acid similarity with HIV-1 RT and both are 
heterodimers of p51 and p66 subunits. The interactions between subunits are thought to be important 
for function and differ slightly between FIV and HIV as p51HIV-p66FIV and p51FIV-p66HIV 
chimeric RTs are less processive than their counterpart wild-type RTs [43]. Another slight structural 
difference is suggested by the fact that substitution into FIV RT of residues that contribute to NNRTI 
sensitivity in HIV-1 RT, does not render it drug susceptible [44] whereas the opposite chimera confers 
NNRTI resistance on HIV. Overall, though, FIV RT behaves in a very similar manner to other 
lentiviral RTs; utilising Mg
2+ as a cofactor, able to function efficiently at the low dNTP concentrations 
present in non-dividing cells and possessing a similarly poor fidelity of replication that, with 
recombination, causes the high level of viral mutation [45,46].  Viruses 2011, 3        
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Regulation of mutation rate is critical to lentiviral survival: it must be fast enough to escape the 
immune system, counteract restriction factors (and eventually to infect new hosts and species), but also 
constrained to prevent excessive mutation limiting production of viable viral particles. Like the   
non-primate lentiviruses CAEV, EIAV and Visna virus, FIV encodes a deoxyuridine triphosphatase 
(dUTPase) [47]. This enzyme reduces levels of dUTP by converting it to dUMP, a precursor for dTTP 
synthesis, and hence limits uracil misincorporation during reverse transcription. In dividing cells, 
cellular dUTPase levels are higher and dUTP levels are low, but in non-dividing cells the reverse is 
true and virally encoded enzymes are vital. dUTPase- FIV mutants, like their EIAV counterparts, are 
able to productively infect dividing cells at or near wild-type levels, but are unable to replicate in 
primary macrophages [47,48]. When FIV dUTPase deletion mutants are used to infect domestic cats, 
they are able to establish a productive infection, but the virus burden is reduced and the genomic 
mutation rate is five times greater in primary macrophages, which are non-dividing, than in actively 
dividing T cells. This leads to changes in the tissue distribution of the virus [49]. The dominant 
mutations are G to A transitions, consistent with uracil misincorporation [49]. The FIV dUTPase is 
remarkably similar in structure and mechanism to the E.coli dUTPase [47] and is likewise active as a 
trimer [50]. The presence of a dUTPase in other parts of the genome of type B and D retroviruses 
suggests that it may have been acquired horizontally [51–53]. Interestingly, primate lentiviruses do not 
encode a dUTPase although there is evidence that an ancestral version may have evolved into part of 
the gp120 envelope gene [54,55]. Their strategy to limit uracil misincorporation is not yet clear, 
although it is possible that HIV-1 achieves this by an association between the Vpr protein and uracil 
N-glycosylase, which removes misincorporated uracil [56]. 
The genome may also mutate during reverse transcription by the action of host cell APOBEC3 
proteins. These are a family of cytidine deaminases which act upon single stranded DNA during 
reverse transcription and convert cytosine to uracil, introducing a G to A mutation in the viral RNA. 
Different members of the APOBEC3 family have been shown to act against retroviral infection; in 
feline cells APOBEC3H and APOBEC3CH proteins mutate the FIV genome, and are counteracted by 
the viral Vif protein [57]. HIV-1 Vif targets the APOBEC3 protein to an E3 ubiquitin ligase complex, 
leading to polyubiquitination and degradation by the proteasome. This is thought to occur via an 
interaction with Elongin C (EloC), part of an E3 ligase complex. The anti-APOBEC3 activity of FIV 
Vif is dependent on an EloC interacting motif with the sequence TLQRLA, suggesting that it uses an 
analogous mechanism to that of HIV-1 [58]. However, their mechanisms are not similar enough to be 
able to substitute for one another, as FIV Vif is unable to counteract human APOBEC3 proteins [58]. Vif 
is crucial to FIV and HIV replication in vivo, as viruses in which Vif is deleted barely replicate [59,60]. 
4. Integration 
The reverse transcribed genome is part of a nucleoprotein structure known as the pre-integration 
complex (PIC) which is translocated to the nucleus where the viral genome is integrated into the host 
cell DNA. A factor known as LEDGF/p75 (Lens Epithelium Derived Growth Factor), a host cell factor 
whose putative role is in transcriptional coactivation, interacts directly with lentiviral integrases and is 
thought to be responsible for tethering the viral integrase (IN) to host cell chromatin [61]. The 
interaction is specific to lentiviruses [61,62] and there is a suggestion that LEDGF/p75 may protect Viruses 2011, 3        
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FIV (and HIV) IN from proteasomal degradation [63]. FIV IN doesn’t contain a nuclear localization 
signal (NLS) but, like HIV-1 IN, localizes to the nucleus when LEDGF/p75 is present and is seen in 
the cytoplasm when it isn’t [64]. Although other proteins, such as transportin-3 (TNPO3) have been 
proposed as nuclear import shuttles for the PIC, FIV IN appears to be at best minimally dependent on 
it for nuclear import [65], and the mechanism remains elusive, although it may depend on integrase 
multimerisation [66]. 
Multimerisation of the integrase is important for its catalytic functions [67]. The N-terminus 
chelates zinc which induces multimerisation and increases catalytic activity [68–72]. Integration 
proceeds in three steps: firstly, the 3' ends of the viral DNA are processed to remove two nucleotides 
and leave CA overhangs. The 3' ends are then joined to the 5' ends of cleaved target DNA, leaving a 
gapped intermediate. Finally the gaps are repaired and the 5' ends are ligated. Like HIV-1 IN, FIV IN 
uses Mg
2+ or Mn
2+ as a cofactor, and contains 3 domains: N and C terminal domains which are needed 
for 3'end processing and joining, and a catalytic domain in the core (CCD) [73]. The predicted three 
dimensional structure of the FIV IN CCD is almost identical to that of HIV-1 [74] and despite lower 
sequence similarity across the rest of IN and other proteins, phylogenetic analysis places the FIV CCD 
as the closest relative of HIV and SIV CCDs. Lending support to the structural and phylogenetic 
findings, integrase strand transfer inhibitors (INSTIs) appear to block FIV replication as efficiently as 
HIV-1 replication [74]. However, FIV displays a slightly different integration site preference from that 
of HIV-1 [75,76]. 
5. Transcription and Nuclear Export 
Transcription of the HIV-1 genome is transactivated by binding of the viral Tat protein to the TAR 
loop in the nascent RNA strand at the 5' end of the genome. FIV contains no predicted TAR-like 
structure. It contains an accessory gene, OrfA (also known as Orf2) with limited sequence similarity to 
Tat which has been shown to transactivate transcription from the FIV LTR to varying degrees [77–79]. 
This protein does not bind directly to the FIV LTR but has been suggested to act in conjunction with 
unidentified cellular transcription factors [79]. The FIV LTR contains known cis-acting elements 
including binding sites for AP1, AP4, C/EBP, NF1 and ATF [80–83] of which the AP4/AP1 and ATF 
sites appear to be required for full basal promoter activity [77,84–86]. The AP1, C/EBP and ATF 
motifs have been suggested to co-operate to enhance transcriptional activity in conjunction with OrfA. 
Basal promoter activity in FIV is similar to that of CAEV and Visna virus, and is significantly higher 
than for HIV [87,88]. Visna and CAEV Tat proteins contain an important cluster of Cys residues at 
their C-termini [89], and when a homologous region in FIV OrfA was deleted, transactivation of the 
FIV LTR was blocked, suggesting that these three viruses use similar methods of transcriptional 
control [79].  
Lentiviral transcripts contain multiple splice sites for qualitative and quantitative control of 
expression of the various genes products. Control of splicing is therefore important to the lentiviral 
lifecycle and changes in regulation of exonic and intronic splicing silencers (ESS and ISS) and other 
protein families involved in splicing regulation have been shown to occur during HIV-1 infection of 
CD4+ T cells [90]. The ESS and ISS families bind to sites within exons and introns respectively and 
reduce the likelihood of nearby sites being used as a splice junction. FIV OrfA has been shown by Viruses 2011, 3        
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microarray analysis to downregulate expression of hnRNPA, hnRNPA2B1 and hnRNPH [91]; proteins 
that regulate ESSs and ISSs, alongside 4 SR proteins that are required for the selection of alternative 
splice sites and removal of constitutively spliced introns [91]. Three snRNP subunits of the 
spliceosome were also found to be modulated by the presence of OrfA [91]. 
A consequence of encoding multiple splice sites within one transcript is the presence of introns 
which would normally prevent nuclear export. Lentiviruses encode a Rev protein, expressed from a 
fully-spliced viral mRNA. Rev shuttles back into the nucleus to allow export of partially spliced and 
unspliced viral transcripts by binding to the Rev-response element (RRE), a highly structured part of 
the RNA genome, and to the nuclear export protein CRM-1 (exportin-1), which shuttles Rev and its 
target RNA out of the nucleus. Unlike the primate lentiviruses, but similar to CAEV and BIV, the first 
coding exon of FIV rev overlaps env and is in the same open reading frame [92–94]. HIV-1 Rev has 
two functional domains: the first contains an arginine-rich region thought to recognize and bind to the 
RNA of the RRE, and a nuclear localization signal [95]. There is sequence similarity between this 
domain in HIV-1 and FIV [96]. The C-terminal domain contains the nuclear export signal [97]. In the 
primate lentiviruses this is a conserved 11 amino acid, leucine rich region that mediates binding to 
CRM-1, but in FIV the region is longer, and the leucines are spaced further apart and are interspersed 
with other hydrophobic residues [98]. This has since been identified as part of a family of Crm-1 
dependent nuclear export signals including that of GAPDH and human U5snRNP [99], and can 
substitute for the HIV-1 Rev leucine-rich domain [100]. In the primate lentiviruses the RRE overlaps 
the middle of the env ORF, making mutagenesis of the RRE difficult without disrupting Env function, 
but in FIV the RRE resides at the very 3'end of the env ORF, making mutagenic studies possible. The 
RRE folds into a conserved stem-loop of around 150 nts and it appears that the entire structure except 
for the very tip (stem 6 and the loop) is critical for Rev function: structural perturbation of any of the 
other 5 stems disrupts FIV replication [101]. 
6. Packaging and Assembly 
Translation commences from the fully spliced Rev transcript, and increasing Rev concentration 
allows the transport and translation of the partially spliced and unspliced (genomic) RNAs. Retroviral 
Gag proteins are translated from the genomic transcript and perform multiple functions according to 
the stage of the viral lifecycle. Inside the host cell, the Gag protein identifies and captures the 
viral  genomic RNA for packaging, isolating it from the wealth of other RNAs present in the 
cytoplasm [102]. Although the cellular location for this interaction is unknown in any retrovirus, recent 
experiments in FIV suggest that it may occur at the cytoplasmic face of the nuclear envelope [103]. 
The stringent specificity of Gag for the viral genomic RNA is mediated by the nucleocapsid (NC) 
domain, which recognizes within it one or more packaging signals (Ψ). In some retroviruses Ψ is 
positioned between the major splice donor (mSD) and the Gag AUG, and thus is retained only in 
genomic and not in spliced viral RNAs. In FIV Ψ appears to be bipartite, lying partly within the first 
250 [104] nt of the 5'UTR, and partly in the start of the gag gene [104–107]. Intriguingly, the 
intervening region, containing the mSD through to the Gag AUG, is neither structurally nor 
functionally important as it can be deleted or replaced with heterologous sequence without affecting 
packaging [108]. Although there is little sequence conservation between these regions of FIV and other Viruses 2011, 3        
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lentiviruses, the recognition of viral genomic RNA must occur via similar mechanisms as FIV Gag can 
cross-package HIV-1 and SIV Ψ-containing RNA, and vice-versa [109]. The lack of sequence 
similarity between these viruses suggests that the structural context of these binding sites is very 
important. Genomic RNA dimerization is closely linked to packaging and the in vivo dimerization 
initiation site in FIV has not been identified, but in vitro a palindromic sequence within the gag ORF 
initiates dimerization [110]. How the virus regulates the balance between translation and packaging of 
its genomic RNA is not clear, however there is evidence from biochemical probing, free energy 
minimization and phylogenetic comparisons that the genomic RNA structure can adopt two different 
conformations[110]. In one of these the putative dimerization initiation site is exposed suggesting it 
may favour RNA packaging. The ability to adopt either structure is highly conserved amongst FIV 
domestic cat isolates[110]. 
The RNA is captured by a high affinity interaction between the NC domain of the Gag polyprotein 
and the RNA, but it is likely that the entire Gag protein plays a role in Ψ recognition and binding. NC 
contains two Zinc knuckle domains which are conserved amongst lentiviruses and most other 
retroviruses, and contain the sequence Cys-X2-Cys-X4-His-X4-Cys. The proximal domain plays a 
more dominant role in binding to the FIV genome than the distal domain and two lysine residues in the 
linker region between the Zn knuckle domains are also crucial [111]. In FIV, the two zinc knuckles 
have also been observed to contribute towards nucleic acid annealing, minus strand DNA transfer, the 
level of dimerization seen, hybridization of tRNA to the PBS, and initiation of reverse transcription [112]. 
With the exception of some highly conserved motifs, the overall sequences of Gag proteins are 
highly variable between lentiviruses. Interestingly, the MA protein sequence appears much less 
conserved than CA or NC. This divergence is maintained even within different strains of FIV, as the 
Gag proteins from different species-specific strains of FIV vary by 25–30% [113]. However, structural 
predictions of FIV Gag suggest that the protein adopts a similar structure to that of HIV-1 and EIAV 
Gag proteins [113], with MA, CA and NC domains present in similar numbers and with similar 
arrangements of secondary structural elements. 
Retroviral Gag proteins comprise the main structural components of virions, and Gag alone 
self-assembles in vitro into virus-like particles. The appearance of these is similar in FIV to other 
lentiviruses [114,115]. The CA domain is known to facilitate Gag-Gag interactions via a dimerization 
interface, and cross-reactivity of antibodies raised against FIV or other lentiviral CA proteins suggests 
that although sequence conservation is low, they are likely to be structurally similar [116,117]. A 
Pro-Asp salt bridge that is involved in stabilizing CA-CA interactions in other retroviruses is predicted 
to form in all FIV strains [113], and the presence of a conserved major homology region (MHR) also 
suggests that CA-CA interactions develop in a similar manner to that of HIV-1 [118,119]. 
Another function of Gag is the formation and budding of the developing virion. Several motifs are 
important for this purpose; as is the case for most retroviral matrix (MA) domains, myristylation of the 
N-terminus of FIV MA enables its association with the lipid bilayer [115]. The interaction of a patch 
of basic residues in MA with the plasma membrane component phosphatidylinositol-4,5-bisphosphate 
(PIP2) is also thought to be important for viral egress, as perturbation of PIP2 levels affects budding 
[120]. It is possible that this interaction is weaker in FIV than in other lentiviruses as FIV MA contains 
a shortened basic motif and is incapable of substituting for SIV MA unless the basic patch is mutated 
to include two critical lysine residues found in SIV (and HIV-1), although SIV MA can substitute for Viruses 2011, 3        
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FIV MA without affecting viral replication [121]. A patch of hydrophobic residues, near the 
N-terminus that mediates membrane interactions in other retroviruses [122,123], is dispensable in 
FIV [115]. 
Retroviral Gag proteins contain “late” domains which are short motifs that interact with the cellular 
transport and budding machinery and promote viral egress. The PSAP motif in the FIV Gag C-terminal 
peptide p2 is highly conserved and, like the PTAP motif in HIV-1, interacts directly with the ESCRT 
machinery through Tsg101 [124]. This is vital for viral budding and virion morphogenesis and 
maturation [111,124]. Although the overall process is similar there are variations in each retrovirus. 
The N-terminal proline in the FIV PSAP motif does not seem to be involved in late domain function 
unlike in HIV-1 where it is critical [125,126], and human Tsg101 interacts more strongly with residues 
surrounding it than it does with that of HIV-1 [124]. Other late domain interactions in FIV are less well 
understood. The ESCRT-associated protein Alix facilitates virion release in HIV-1 and EIAV via its 
interaction with a YPXL motif, but although an initial study found the similar LxxL motif in FIV to be 
essential [111], in a subsequent study mutation in the motif seemed to have no effect on viral 
morphogenesis [124]. The third type of known retroviral late domain is PPxY, which interacts with E3 
ubiquitin ligases such as Nedd4 to promote ubiquitination of Gag. Ubiquitination is thought to enhance 
interactions with the ESCRT machinery and hence promote viral egress, by unknown mechanisms. 
Although no PPxY motif is present in FIV Gag, it is ubiquitinated by Nedd4-like proteins, and this can 
compensate for mutations in the PT/SAP motif [126]. However, neither the molecular details of this 
nor its relevance during FIV infection is known. 
Gag also binds to Env and incorporates it into virions. HIV-1 Env binds MA via an interaction of 
MA, TIP47 protein and the cytoplasmic tail of Env, although whether an analogous mechanism exists 
in FIV has not been identified [127]. 
Budding of enveloped viruses is prevented in human cells by tetherin: a transmembrane protein that 
anchors the budding virion to the cell surface [128]. Lentiviruses have evolved different ways in which 
to counteract tetherin, suggesting that it is indeed a retroviral restriction factor; these functions are 
encoded by HIV-1 Vpu, HIV-2 Nef and HIV-2 and SIV Env proteins [128–132]. Feline cells also 
express tetherin in response to viral infection; it is able to prevent release of FIV and HIV-1 from the 
cell surface, but intriguingly, does not prevent cell-to-cell spread of the virus, and in the case of a 
CD134-independent strain of FIV, it enhanced syncytial formation [133]. In vivo, this may allow the 
selective expansion of CD134-independent viral variants and promote more efficient cell-to-cell 
spread [133]. Unlike the primate lentiviruses, FIV does not appear to contain a functional tetherin 
antagonist [133], suggesting that tetherin may not be an FIV restriction factor and that conversely FIV 
may have evolved to use tetherin to its advantage. 
OrfA has recently been shown to downregulate CD134 on the surfaces of infected cells [134]; this 
is thought to aid the dissemination of budding virions by minimizing their interactions with the surface 
of the infected cell.  
7. Maturation 
During virion maturation the cleavage of Gag and Gag-Pol precursor polyproteins is performed by 
the viral protease (PR). In the Gag-Pol polyprotein the protease is nestled between p2 and RT and is Viruses 2011, 3        
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monomeric, but it dimerises during budding. PR then cleaves 9 separate proteins from the polyprotein 
precursors: MA, CA, p1, NC, p2, PR, RT, RNase H, dUTPase and IN [135]. The order of this cleavage 
is very important to the formation of a viable virion, and protease inhibitors often function by 
interfering with this [136]. In FIV the cleavage sites are positioned similarly to HIV-1, but are different 
in both amino acid and processing sequence, reflecting a difference in cleavage site preference of their 
PRs [137]. In addition, FIV has a dUTPase to cleave and has fewer spacer peptides. The process of 
cleavage leads to virion maturation and activation of some of the enzymes, which allows the virion to 
infect a new cell. Autoproteolysis of PR in FIV and other retroviruses also regulates its own activity 
[138]. Like HIV-1, FIV PR contains 4 autoproteolysis sites; however, after processing of the 
polyprotein the mature protease is 116 amino acids, whereas in HIV it is 99 amino acids. Despite this 
length difference, and the fact that FIV and HIV-1 PRs share only 23% aa identity, the 
three-dimensional structures are strikingly similar, as they are in all retroviral proteases [139–141]. 
The structures follow a template of repeating secondary structural units: A hairpin with loops (A1 and 
A2), a wide loop (B1, containing the catalytic aspartic acid and B2), alpha-helices (C1 and C2) and a 
second hairpin or B-strand (D1, D2). The loop regions and connections between secondary structural 
elements vary in length and are the main source of structural difference between the retroviral 
proteases (reviewed in [141]). The substrate specificities and the susceptibilities to protease inhibitor 
drugs vary between FIV and HIV-1, and the residues in the active site have been observed to be 
different. FIV prefers Ser at P1’, and Asn/Gln at P1 and Arg at P3, and HIV prefers Asn at P2 and 
Glu/Gln at P2 [142]. Mutation of the FIV active site to include the analogous HIV-1 residues alters the 
order of Gag-Pol processing to more closely resemble that of HIV-1 and increases sensitivity to HIV-1 
protease inhibitors [137]. Such chimeric comparison studies are possible because the three-dimensional 
structures of the enzymes are so similar. It is hoped that such studies will lead to the development of 
broad-based inhibitors against retroviral protease function, that are active against proteases resistant to 
current drugs and that prevent the emergence of drug escape mutants. 
8. Conclusions  
Despite significant sequence divergence from the primate lentiviruses, the molecular biology of FIV 
is strikingly similar. The structures and mechanisms of action of the essential proteins are very closely 
related in most cases, and result in a similar cycle of infection and morphologically indistinguishable 
virions. Differences in genomic organisation in FIV from other lentiviruses, such as the location of the 
RRE, and the lack of overlap of the late domains of Gag with the pol ORF have facilitated delineation 
of the functions of these various elements. However, many aspects of the replication cycle are still 
obscure. In particular, the role of OrfA and its involvement in both transcriptional transactivation and 
splicing regulation remains controversial. Aside from the functions discussed above, it was seen to 
downregulate several E2 ubiquitin conjugating enzymes and one ubiquitin-protein ligase [91]. OrfA 
may therefore limit degradation of viral proteins in the host cell. It may also interfere with antigen 
processing as it downregulates two subunits of the immunoproteasome [91]. It will be very interesting 
to see how such a small protein can have such multifaceted effects on the host cell and the virus. The 
similarities in clinical course of infection between domestic cat FIV and HIV-1 infection are striking 
and many have proposed the use of FIV as a small-animal model for HIV-1 infection. The similarities Viruses 2011, 3        
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in molecular biology between the two viruses add weight to this argument. Interestingly, aside from 
the entry receptor, HIV-1 needs only FIV Vif in order to replicate in feline cells [143], which indicates 
that all of the interactions between HIV-1 and feline cellular components are functional, and again 
highlights the striking similarities in their molecular biology. In remarkable contrast, Vif from 
domestic cat strains of FIV can counteract APOBEC proteins from puma, lion, tiger and lynx, but 
cross-species infection is unproductive, suggesting that in the cells of these animals further restrictions 
to infection with different species-specific FIV strains exist [144] highlighting the differences between 
the different feline species and their individual FIV strains.  
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